CAR-T cell therapy research

Installation of Dominant-Negative Mutations in FAS and TGFβR2 via Base Editing in Primary T Cells

This paper uses base editing to introduce dominant-negative mutations in FAS and TGFβR2 in primary T cells, enhancing their anti-tumor efficacy and persistence in solid tumor models.

In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors

This paper performs in vivo CRISPR screens in human T cells to identify genetic modifiers of T cell function in solid tumors, finding P2RY8-G13 and GNAS as key regulators.

Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors

This study shows that enhancing Fas/FasL signaling improves CAR-T cell bystander killing against antigen-negative tumor cells, reducing antigen escape and improving therapeutic outcomes.

Bicistronic CAR T-cells Against CD70 & Active Integrin β2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia

This paper develops dual-antigen targeting CAR-T cells against CD70 and active integrin β2 to overcome AML antigen heterogeneity and reduce off-tumor toxicity.

Repurposing passenger amplifications as Trojan horses identifies MPZL1 as a potent target for solid cancers

The paper identifies MPZL1 as a therapeutic target in 1q-amplified solid cancers by repurposing passenger amplifications as Trojan horses for targeted therapy delivery.

Identifying Distinct Molecular Response of CAR-T cells to Solid Tumors by Synthetic Single-Cell Transcriptomic Analyses

The paper identifies unique molecular responses of CAR-T cells in solid tumors through single-cell transcriptomic analysis, revealing immunosuppressive subpopulations and PD-1-independent exhaustion-like features.

PTPN2-KO CAR-T Cells Demonstrate Enhanced Effector Function, CNS Infiltration, and Toxicity in a Non-Human Primate CAR-T Model

Neuropilin-1 expression by solid tumors impairs CAR T cell function

This study investigates how Neuropilin-1 (NRP-1) on solid tumors affects CAR T cell function, finding that NRP-1 transfer via trogocytosis may impair CAR T cell activity.

MiniCARbids: Minimalistic human binding domains specifically tailored to CAR T applications

The paper introduces miniCARbids, small human-derived CAR binding domains that show high anti-tumor potency in CAR T cells, outperforming traditional scFvs in some cases.

CD33KO-CD33-mesothelin loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemia

This study designs a CD33-mesothelin loop CAR to enhance iNK cell efficacy against AML by avoiding fratricide and improving cytotoxicity.

Off-the-shelf allogeneic polyclonal CD38KO/CD38-CAR γδT cells for the treatment of T cell malignancies

This paper develops CD38KO/CD38-CAR γδT cells for T cell malignancies, showing they effectively target T-ALL without causing fratricide or GvHD.

Conversion of natural cytokine receptors into orthogonal synthetic biosensors

The paper develops synthetic cytokine receptors by repurposing natural ectodomains to create orthogonal biosensors for targeted cellular responses.

Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma

This paper engineers CCL27 mutants to enhance CAR T-cell efficacy against multiple myeloma by targeting CCR10, achieving results comparable to BCMA CAR-Ts.

SCAN-ACT: Adoptive T Cell Therapy Target Discovery Through Single-Cell Transcriptomics

SCAN-ACT identifies and prioritizes T cell therapy targets for solid tumors using single-cell transcriptomics and multi-omics data, validating targets through experimental methods.

JNK knockdown enhances CAR-T cell cytotoxicity

This study shows that knocking down JNK in CAR-T cells increases their cytotoxicity against ovarian cancer by enhancing granzyme B expression through NFATc1.

CircRNA-based, non-integrated, in vivo panCAR-mediated B cell immune resetting in mouse models and non-human primates

This paper develops circRNA-based in vivo panCAR to achieve comprehensive B cell depletion and reconstitution, showing efficacy in treating B cell disorders and aging in mice and non-human primates.

CART-GPT: A T Cell-Informed AI Linguistic Framework for Interpreting Neurotoxicity and Therapeutic Outcomes in CAR-T Therapy

CART-GPT predicts CAR-T therapy efficacy and neurotoxicity risk using a transformer model trained on 1.12 million single-cell RNA-seq profiles with clinical outcomes.

Healthy B cells: allies or adversaries of CAR-T cell immunotherapy?

This paper develops a mathematical model to study how healthy B-cells affect CAR-T cell therapy outcomes in B-cell cancers, showing their variable impact based on patient-specific factors.

Engineering a Juxtamembrane-Targeting CAR T-Cell Against Mesothelin: A Novel Binder Resilient to Shed Antigen in Ovarian and Pancreatic Cancer

This paper develops a CAR T-cell targeting the mesothelin stump domain, showing comparable cytotoxicity and effectiveness against resistant tumors compared to standard anti-mesothelin CAR T-cells.

IL-7 armed binary CAR T cell strategy to augment potency against solid tumors

This study develops a binary CAR T cell strategy targeting PSCA and MUC1 with IL-7 expression to improve antitumor potency and persistence in pancreatic tumors.

CAR T cell cytotoxic responses are rapidly generated and sensitive to the unligated TCR

This study investigates CAR T cell cytotoxic responses, showing they are sensitive to TCR interactions and can be modulated by inhibitory peptides.

Synergically enhanced anti-tumor immunity of in vivo CAR by circRNA vaccine boosting

This study develops circRNA-based in vivo CAR and vaccines that synergistically enhance anti-tumor immunity in mice.

In vivo screening of TCR-based chimeric antigen receptors for improved anti-tumor functionality

This study screens TCR-based CAR designs to improve anti-tumor efficacy by incorporating CD28 and CD27 costimulatory domains, showing enhanced performance in mouse tumor models.

Programmable microparticles rewire CAR signaling to enable super-physiological expansion of human T cells in vitro

This study uses programmable microparticles to enhance CAR-T cell expansion beyond physiological limits by rewiring signaling pathways.

Inclusion of the ζ-chain drives phosphotyrosine signalling in CD19-CAR T cells

This study investigates how the inclusion of the ζ-chain affects phosphotyrosine signaling in CD19-CAR T cells using phosphoproteomics and inhibitor experiments.

A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy

This paper introduces a modular CAR-Fab platform that improves cancer immunotherapy by enabling rapid target redirection and reducing antigen loss variant escape.

Screening of a pooled library of chimeric antigen receptor T cells based on secretory function

This paper presents a nanovial-based platform for high-throughput functional screening of CAR T cell libraries, identifying CAR constructs with distinct secretion profiles over time.

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia

This paper develops and validates a dual-targeting CAR-T cell therapy for T-ALL that targets CCR9 and CD1a, showing improved efficacy and safety compared to single-targeting approaches.

A balanced CAR-T cell metabolism driven by CD28 or 4-1BB co-stimulation correlates with clinical success in lymphoma patients

Ex vivo profiling of patient CD19 CAR-T cells shows CD28 products skew glycolytic and effector-like while 4-1BB products favor OXPHOS; complete responders show balanced metabolism.

Peptide-Specific CAR T cells Recognize WT1 Promiscuously Presented by Diverse HLA Class II Alleles

This paper develops WT1-specific CAR T cells that recognize the WT1330-348 peptide across 18 HLA-II alleles, enabling broad therapeutic application.